61
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
Condition(s):Chagas Disease; Heart FailureLast Updated:February 8, 2023Recruiting
Valsartan: 512 Clinical Trials, Page 7 of 52
Hide Studies Not Open or Pending
62
Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions
Condition(s):HealthyLast Updated:July 22, 2014Completed
63
Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
Condition(s):Hypertension; ObesityLast Updated:August 3, 2018Unknown status
64
Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions
Condition(s):HealthyLast Updated:July 22, 2014Completed
65
Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Condition(s):Hypertension; DyslipidemiaLast Updated:February 24, 2021Withdrawn
66
” Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD “
Condition(s):Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection FractionLast Updated:November 2, 2022Not yet recruiting
67
Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
Condition(s):HypertensionLast Updated:February 26, 2016Terminated
68
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
Condition(s):HypertensionLast Updated:September 5, 2021Completed
69
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
Condition(s):Heart Failure, SystolicLast Updated:May 24, 2022Completed
70
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
Condition(s):Hyperlipidemia; HypertensionLast Updated:March 10, 2017Completed